Copertina

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	British Journal of Pharmacology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Psychedelic research, assisted therapy and the role of the anaesthetist: A review and insights for experimental and clinical practices
di: Gisela Lima, et al.
Pubblicazione: (2024)

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials
di: Thi Viet Ha Nguyen, et al.
Pubblicazione: (2025)

A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials
di: Anna Margarete Maria Thurner, et al.
Pubblicazione: (2025)

Exploring new avenues: Psychedelic‐assisted therapy for young people
di: Ioanna Artemis Vamvakopoulou, et al.
Pubblicazione: (2026)

A scoping review of disease‐modifying antirheumatic drug nonadherence in rheumatoid arthritis: Measurement, prevalence and implications for clinical practice
di: Lauren Fraser, et al.
Pubblicazione: (2025)

Medication adherence during the run‐in phase of clinical trials: A systematic review of methodological and reporting rigour
di: Non Davies, et al.
Pubblicazione: (2025)

Mobile applications on app stores for deprescribing: A scoping review
di: Lina Okati, et al.
Pubblicazione: (2024)

Spotlight commentary: Innovations in clinical trials
di: Nataša Hudej, et al.
Pubblicazione: (2025)

Educate to medicate: A clinical pharmacologist's perspective
di: Robert Likic, et al.
Pubblicazione: (2025)

Medication review interventions for adults living with advanced chronic kidney disease: A scoping review
di: Cathy Margaret Pogson, et al.
Pubblicazione: (2024)

“Doctor, would it surprise you if there were prescribing errors in this patient's medication?” Identifying eligible patients for in‐hospital pharmacotherapeutic stewardship: A matched case‐control study
di: Rashudy F. Mahomedradja, et al.
Pubblicazione: (2024)

Implementability of opioid deprescribing interventions at transitions of care: A scoping review
di: Jeffery Wang, et al.
Pubblicazione: (2024)

Why and how do we perform physical examination(s) in clinical trials? A use case of drug intervention trials in type 2 diabetes mellitus
di: Julia Kopanz, et al.
Pubblicazione: (2025)

A scoping review of quality prescribing indicators, rules and criteria for primary care
di: James Nind, et al.
Pubblicazione: (2026)

Why do healthy volunteers participate in clinical trials?
di: Thijs van Iersel, et al.
Pubblicazione: (2026)

Co‐design–related approaches in medication safety for people with dementia: A scoping review
di: Zena El‐kadomi, et al.
Pubblicazione: (2026)

Association between use of lubiprostone and headache: A systematic review and meta‐analysis of randomized controlled trials
di: Satoru Mitsuboshi, et al.
Pubblicazione: (2025)

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience
di: Juliette A. van den Noort, et al.
Pubblicazione: (2025)

External validation of the BAN‐ADHF diuretic‐resistance score in the DAPA‐RESIST clinical trial
di: Dominic M. Alfonso, et al.
Pubblicazione: (2026)

Strategies employed and experiences associated with the implementation of pharmaceutical services and interventions in geriatric wards: A scoping review
di: Alan Maicon de Oliveira, et al.
Pubblicazione: (2024)

Frailty in clinical drug trials: Frailty assessments, subgroup analyses and outcomes
di: Tu N. Nguyen, et al.
Pubblicazione: (2024)

Justifying and reporting the use of stress protocols in pre‐clinical experiments that use animals
di: Andria Michael, et al.
Pubblicazione: (2026)

Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approach
di: Jules A. A. C. Heuberger, et al.
Pubblicazione: (2025)

Medication adherence for people with acquired communication disorders: A systematic review
di: Shauna Bell, et al.
Pubblicazione: (2024)

Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover‐design trial
di: Alexander Hincker, et al.
Pubblicazione: (2024)

The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview
di: Elise Le Flohic, et al.
Pubblicazione: (2024)

β‐Blockers and risk of neuropsychiatric disorders: A systematic review and meta‐analysis
di: Lujain Ez Eddin, et al.
Pubblicazione: (2024)

The evolving therapeutic landscape of spinal muscular atrophy – A scoping review of investigational agents, emerging delivery technologies and strategic innovations
di: Andrej Belančić, et al.
Pubblicazione: (2026)

Natural product pharmacology: the British Journal of Pharmacology perspective
di: Xin Wang, et al.
Pubblicazione: (2024)

Overcoming barriers to adherence through innovative injectable medications: A systematic review of therapeutic options for cardiovascular disease, reported adherence, and perspectives on their use
di: Beata Bajorek, et al.
Pubblicazione: (2025)

Transgender people in clinical trials of drugs and biologics: An analysis of ClinicalTrials.gov from 2007 to 2023
di: Zachary Schonrock, et al.
Pubblicazione: (2024)

Incorporating transgender and nonbinary participants in phase 1 clinical drug trials: Current knowledge gaps and considerations
di: Lauren E. Walker, et al.
Pubblicazione: (2024)

RETRACTED: Effects of different antihypertensive drug classes on central and ambulatory blood pressure in resistant hypertension: A randomized clinical trial
di: Juan Carlos Yugar‐Toledo, et al.
Pubblicazione: (2025)

Main factors associated with variability in the assessment of the objective response rate. A re‐analysis of the PHEREXA phase 3 clinical trial
di: Gennaro Daniele, et al.
Pubblicazione: (2026)

A systematic review of medication adherence and mortality in chronic disease: Implications for clinical guidelines and policy
di: Jessica Hamuy Blanco, et al.
Pubblicazione: (2025)

Impact of treosulfan exposure on clinical outcome after allogeneic stem cell transplantation in children: A substudy of 2 phase 2 trials
di: Krzysztof Kalwak, et al.
Pubblicazione: (2024)

Letter to the editor concerning the article: ‘The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview’
di: Tamás Ágh, et al.
Pubblicazione: (2025)

Compartmentalisation in cAMP signalling: A phase separation perspective
di: Milda Folkmanaite, et al.
Pubblicazione: (2025)

Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review
di: Stavros Topouzis, et al.
Pubblicazione: (2025)

Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing
di: Simon K. Wellenberg, et al.
Pubblicazione: (2025)